Ketamine therapy and the developing brain: what the animal data means for adult patients

A study published in mid-2025 made a specific and uncomfortable claim: ketamine kills neurons in juvenile rat brains at doses that leave adult rat brains largely intact (https://pubmed.ncbi.nlm.nih.gov/42240040/). If you are an adult weighing ketamine therapy for depression or treatment-resistant mood disorders, that headline probably landed like a warning shot. It deserves a serious answer -- not reassurance, not dismissal, but an honest look at what the data actually shows and what it does not.

We cover this topic because our patients read primary research and ask sharp questions. If you want the broader context on how we approach depression and mental health treatment at NoMi Beach Health, our high-performer mental health guide is a good place to start.

What the rat study actually found

Researchers exposed juvenile rats (postnatal day 7, roughly equivalent to a late-term human fetus or newborn) and adult rats to the same ketamine protocol. They measured markers of apoptosis -- programmed cell death -- in several brain regions afterward. The juvenile animals showed significantly more neuronal death than the adults (https://pubmed.ncbi.nlm.nih.gov/42240040/).

This is not a new finding in principle. The framework goes back to work by Olney and colleagues in the early 2000s, who showed that NMDA receptor antagonists -- the drug class ketamine belongs to -- could trigger apoptotic neurodegeneration in developing rodent brains during what is called the brain growth spurt (https://pubmed.ncbi.nlm.nih.gov/12408230/). What the 2025 study adds is a cleaner head-to-head comparison between age groups using current methodology.

The mechanism makes biological sense. During early brain development, NMDA receptors are expressed at unusually high density because the brain is actively pruning and strengthening synapses. NMDA receptors are essentially the traffic signals for that process. Block them during the critical window -- which in humans spans the third trimester through early childhood -- and you disrupt signaling in a way that can trigger cell death. Adult brains have far fewer NMDA receptors per unit area, and the synapse-pruning window is closed, so the same blockade produces a much weaker apoptotic response.

Why this matters less for adult patients than the headline suggests

The honest answer is that the 2025 rat study is not a study of adult clinical ketamine therapy. It is a developmental neurotoxicity study, and the two questions are genuinely different.

For adult patients with treatment-resistant depression, the evidence base looks like this. In a landmark randomized controlled trial published in the American Journal of Psychiatry, 47% of treatment-resistant patients responded to ketamine infusion versus 20% to midazolam control at 24 hours -- a clinically meaningful difference in a population where standard antidepressants had already failed (https://pubmed.ncbi.nlm.nih.gov/23982301/). The antidepressant effect involves BDNF signaling, synaptogenesis, and glutamate system modulation that is distinct from simple NMDA blockade in a passive developing brain (https://pubmed.ncbi.nlm.nih.gov/29532791/).

A systematic safety review in Lancet Psychiatry found that the most common adverse effects in clinical trials were dissociation, dizziness, nausea, and transient blood pressure elevation -- not cognitive decline or markers of neuronal death at the doses and frequencies used (https://pubmed.ncbi.nlm.nih.gov/29656110/). A separate tolerability analysis covering hundreds of infusion patients found no pattern of cumulative neurocognitive harm at standard therapeutic doses (https://pubmed.ncbi.nlm.nih.gov/26035186/).

What remains genuinely uncertain: the very long-term effects of repeated maintenance infusions over years, effects in patients with pre-existing neurological conditions, and optimal dosing intervals. We say that clearly because pretending certainty where none exists is not medicine.

What about esketamine and FDA approval

Esketamine (Spravato) -- the S-enantiomer of ketamine delivered intranasally -- is the only form FDA-approved specifically for depression. It carries two indications: treatment-resistant depression (TRD), and major depressive disorder with acute suicidal ideation or behavior (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211243s013lbl.pdf).

The approval required clinical trials that the FDA reviewed for safety signals, including cognitive effects. The label does carry a risk evaluation and mitigation strategy (REMS) requiring in-office administration and monitoring -- not because neuronal death was demonstrated in adults, but because of dissociation risk and abuse potential.

Recent research has continued to expand the picture. A 2025 target trial emulation study looked at esketamine use in patients with cancer-related depression and found associations with improved clinical outcomes and survival that deserve further prospective study (https://pubmed.ncbi.nlm.nih.gov/42235877/). That data is early but noteworthy -- it pushes back on a simple "ketamine is neurotoxic" reading of the animal literature.

The pediatric question is legitimately different

Here is where we do exercise real caution. A 2025 pilot randomized trial published on PubMed tested ketamine for suicidal ideation in a pediatric emergency department (https://pubmed.ncbi.nlm.nih.gov/42234079/). The results suggested rapid reduction in suicidal ideation -- which is a meaningful clinical signal in a setting where the alternative may be no effective acute intervention.

But the rat study and the developmental neurotoxicity literature mean that pediatric ketamine use carries a different risk calculus than adult use. The developing human brain is not a juvenile rat brain, and emergency ketamine doses are not anesthetic doses administered repeatedly. Still, we would never be dismissive of those concerns in a younger patient, and any clinician who is should be pressed on it.

For adult patients reading this: the developing-brain findings are not your story. They are the reason ketamine should not be used casually or without clinical oversight in children -- and they are a reasonable argument for why we take dosing, frequency, and monitoring seriously at every age.

How we think about ketamine therapy for adults at NBH

We approach ketamine as a tool with a specific indication, not a general wellness treatment. What clinicians look for before recommending ketamine:

• A confirmed diagnosis of treatment-resistant depression (meaning two adequate antidepressant trials at therapeutic dose have failed), or major depressive disorder with active suicidal ideation where rapid response is clinically urgent.
• A cardiovascular workup, because ketamine transiently elevates blood pressure and heart rate.
• A careful psychiatric history -- active psychosis and certain dissociative disorders are contraindications.
• A frank conversation about fertility, if relevant, and about drug interactions including the CYP450 metabolism picture, which shapes how individuals process and clear ketamine (https://pubmed.ncbi.nlm.nih.gov/42240275/).
• Informed consent that includes honest language about what we know, what we do not know, and what monitoring will look like.

We do not use ketamine as a first-line treatment. We do not use it because a patient read about it online. And we do not use the animal neurotoxicity data to scare patients away from a treatment that has genuine evidence in adults -- because that would be as dishonest as ignoring the data entirely.

If you are already on an antidepressant or another psychiatric medication and wondering whether ketamine could help where your current regimen has not, the ketamine therapy overview on our site walks through what a supervised course actually looks like. And if you are not sure whether your symptoms meet the bar for treatment-resistant depression versus undertreated depression or something else entirely, that distinction matters and is worth sorting out first -- we also address the full ADHD and mood disorder evaluation picture in our adult ADHD evaluation post, since these conditions overlap more than most people realize.

The honest bottom line

The 2025 juvenile-versus-adult rat comparison is good science. It adds to a consistent body of evidence that the developing brain is genuinely more vulnerable to NMDA antagonists than the mature brain -- a finding with real implications for pediatric anesthesia, for neonatal ketamine exposure, and for any future discussion of ketamine in children and adolescents.

For adults with treatment-resistant depression: this study does not change the risk-benefit calculation in a way that should push you away from a therapy with real controlled-trial evidence behind it. What it does reinforce is that ketamine is not a casual treatment, that monitoring matters, and that the clinician you work with should be comfortable saying "we are still learning" about long-term maintenance protocols.

We are comfortable saying that. We are also comfortable saying that for the right adult patient -- someone who has tried standard antidepressants, had an honest evaluation, and been cleared medically and psychiatrically -- ketamine therapy is one of the more evidence-backed options in a field that has needed new tools for a long time.

If you want to find out whether you are that patient, book a new-patient visit through our mental health services page or call us at (786) 744-5152. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) will review your history, your prior treatment record, and your labs -- and give you a straight answer about whether ketamine belongs in your plan.